Vivos Inc. has announced the issuance of U.S. Patent No. 12,521,452 B2, titled "Radiotherapy Gel and Method of Preparing the Same," granted by the United States Patent and Trademark Office on January 13, 2026. The patent protects critical advancements in the company’s proprietary Precision Radionuclide Therapy platform, which underpins its RadioGel® and IsoPet® products. Additionally, Vivos has filed a new patent application covering the use of its hydrogel technology as a carrier for a range of therapeutic agents, including anti-cancer and gene therapy agents, enabling timed release once formed into a gel after injection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644224-en) on January 28, 2026, and is solely responsible for the information contained therein.